<DOC>
	<DOCNO>NCT02479178</DOCNO>
	<brief_summary>BIND-014 ( docetaxel nanoparticles injectable suspension ) study patient advanced urothelial carcinoma , cervical cancer , cholangiocarcinoma carcinomas biliary tree squamous cell carcinoma head neck . Ferumoxytol image also investigate US sit exploratory endpoint .</brief_summary>
	<brief_title>A Study BIND-014 Patients With Urothelial Carcinoma , Cholangiocarcinoma , Cervical Cancer Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Diagnosis advance urothelial carcinoma , cervical cancer , cholangiocarcinoma carcinomas biliary tree squamous cell carcinoma head neck . 2 . Progressive disease â‰¥ 1 prior chemotherapy regimen . 3 . Patients brain metastasis eligible asymptomatic neurologically stable least 4 week take medication contraindicate 4 . Chemotherapy must complete least 4 week prior initiation study medication 5 . ECOG performance status 01 6 . Tumors must measurable disease per RECIST ( version 1.1 ) ; 7 . Female male , 18 year age old 8 . Adequate organ function 9 . Life expectancy &gt; 3 month 1 . Current treatment another therapeutic clinical trial 2 . Prior treatment docetaxel within 6 month enrollment 3 . Stage II , III IV cardiac failure 4 . Carcinomatous meningitis 5 . Ongoing cardiac dysrhythmias 6 . Peripheral neuropathy 7 . Serious concomitant condition 8 . Pregnant breast feed 9 . Known sensitivity ferumoxytol 10 . Hypersensitivity polysorbate 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>